Breast Cancer Coverage from Every Angle

Javier Cortés, MD, PhD, on Clinical Interpretation: First-Line Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer

Posted: Wednesday, January 12, 2022

Javier Cortés, MD, PhD, of the International Breast Cancer Center, discusses how pembrolizumab might contribute to first-line treatment of patients with inoperable or metastatic triple-negative breast cancer and his recommendations for the best way to integrate this agent with chemotherapy in this cohort.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.